A5051319889- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lung Cancer Treatments and Mutations
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Immunodeficiency and Autoimmune Disorders
- Chemotherapy-induced cardiotoxicity and mitigation
- Hemoglobinopathies and Related Disorders
- Cancer Treatment and Pharmacology
- Advanced Proteomics Techniques and Applications
- Blood properties and coagulation
- Lung Cancer Research Studies
- Genetic Neurodegenerative Diseases
- Porphyrin Metabolism and Disorders
- DNA Repair Mechanisms
- CNS Lymphoma Diagnosis and Treatment
- Testicular diseases and treatments
- Cardiac tumors and thrombi
- Reproductive Biology and Fertility
- Breast Cancer Treatment Studies
- Ovarian cancer diagnosis and treatment
Uppsala University
2017-2025
Gävle Hospital
2024
King Faisal Specialist Hospital & Research Centre
2012
Background: Poly (ADP-ribose) polymerase 12 (PARP12) plays a crucial role in DNA damage response (DDR) through repair, maintaining genomic stability. Mutations PARP12 contribute to instability, leading cancer progression. Targeting mutants with small molecule inhibitors offers promising therapeutic strategy. Objective: This study aims identify potent for using molecular docking-based virtual screening from the National Cancer Institute (NCI) compound library, followed by dynamics (MD)...
The Swedish Lymphoma Register (SLR) was initiated in the year 2000 with aim to monitor quality of care diagnostics, treatment and outcome all lymphomas diagnosed nationally among adults. Here, we present first systematic validation SLR records as a basis for improved register patient care.
Summary Routine follow‐up for diffuse large B‐cell lymphoma have been shortened to 2 years when event‐free survival at 24 months (EFS24) emerged as a new milestone. In the present study, we aimed determine whether achievement of this milestone affected overall (OS). We compared OS that an age‐ and sex‐matched population, analysed other factors governing OS, reviewed causes death. Data were collected from Swedish Cancer Registry individual patient’s records. included 1169 adult patients five...
The standard treatment for diffuse large B cell lymphoma (DLBCL) is rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine (VCR), and prednisone). Maintaining high dose intensity of cytotoxic has been associated better outcome but little known about the role maintaining VCR. This study aimed to answer whether omission due neurotoxicity affects patient outcome. A Swedish cohort patients primarily treated curative intent DLBCL or high-grade malignant was retrospectively analyzed. In...
Background: Patients with certain autoimmune diseases (AID) have an increased risk of developing diffuse large B-cell lymphoma (DLBCL). However, the occurrence AID in patients DLBCL as well impact on outcome has not been extensively studied. The main purpose this study was to establish AIDs a population-based cohort and compare outcomes or without treated rituximab(R)-CHOP/CHOP-like treatment. We also aimed analyse gender differences potential role different frequency treatment-associated...
Aiming to accommodate the unmet need for easily accessible biomarkers with a focus on biological differences between haematological diseases, diagnostic value of plasma proteins in acute leukaemias and lymphomas was investigated. A multiplex proximity extension assay (PEA) used analyze 183 samples from 251 leukaemia lymphoma patients compared 60 healthy controls. Multivariate modelling using partial least square discriminant analysis revealed highly significant distinct disease subgroups The...
Abstract Background Cardiovascular toxicity is a notorious complication of doxorubicin (DXR) therapy for diffuse large B-cell lymphoma (DLBCL). Although surveillance well-known biological markers cardiovascular disease (CVD) as NTproBNP and Troponins may be helpful, there are no established to monitor evolving CVD during treatment. New possibilities have arisen with the emergence newer techniques allowing analysis plasma proteins that can associated disease. Proximity Extension Assay one...
Fanconi anemia is a rare chromosomal instability disorder associated with developmental abnormalities, bone marrow failure, and heightened susceptibility to leukemia other cancers. It an autosomal recessive genetic disorder, necessitating both parents carry the faulty gene. Diagnostic methods include blood tests, chromosome breakage assessments, testing. While there no cure, treatments encompass transfusions, transplants, gene therapy, patients requiring regular check-ups, supportive care,...
e14073 Background: FOLFOXIRI demonstrated tolerable toxicities and improved efficacy compared to FOLFIRI in MCRC a phase III trial. Oral C has similar IV 5-FU might substitute the regimen. Methods: This is I-II prospective trial using fixed dosed of capecitabine (C), oxaliplatin (O), bevacizumab (B) combination escalating doses Irinotecan (I) metastatic locally advanced unresectable CRC patients (pts). The objectives study were define recommended dose (RD) I with C, O B, safety combination....